This page shows the latest enasidenib news and features for those working in and with pharma, biotech and healthcare.
In addition, Servier will also gain the co-commercialisation responsibilities for Bristol Myers Squibb-partnered Idhifa (enasidenib), which is also indicated for AML.
irrespective of their expression of the PD-L1 biomarker. There has been further bad news for BMS after its recently-acquired Celgene unit withdrew a marketing application for Idhifa (enasidenib) as
If approved, the CC-486 will round out an AML franchise at Celgene that along with Vidaza also includes Agios-partnered Idhifa(enasidenib), a targeted second-line therapy for patients with
or AML with myelodysplasia-related changes (AML-MRC) – while Celgene/Agios claimed approval for Idhifa (enasidenib) as a treatment for AML patients with the IDH2 mutation.
Idhifa ( enasidenib or AG-221) has been cleared for the treatment of relapsed or refractory acute myeloid leukaemia (AML) in patients with an IDH2 mutation, a group that accounts for somewhere ... At Celgene, enasidenib will slot into its blood cancer
First approval for enasidenib could be just six months away. Celgene could be just six months away from getting its first approval for enasidenib, a first-in-class drug for acute ... Celgene filed for approval of enasidenib as a treatment for relapsed,
More from news
Approximately 1 fully matching, plus 5 partially matching documents found.
We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....